The world is facing a common threat in the form of a deadly Coronavirus pandemic. After facing the wrath of the pandemic, the vaccine doses were manufactured to beat the virus. To make the fight a tough one, the pandemic is changing its form. After the emergence of the new Omicron variant, a debate on the variant likely to escape the immunity had started.
This gave birth to a demand that a third dose(booster) should be given to the people so that the vaccine can be stopped from infecting more people. States like Karnataka, Maharashtra have urged the Union government to permit the booster dose before the Omicron spreads its wings.
Amid this, the Pune-based Serum Institute of India(SII) which manufactured Covishield had reached out to the Central government's Subject Expert Committee (SEC) to seek approval for the booster dose. The Committee went through the application filed by the biotechnology company.
However, the booster dose did not get approval from the committee reportedly. The reason for this is that the committee is said to have asked Pune-based Biotechnology SII to submit more data on the vaccine dose in this regard.
Media reports say that the Subject Expert Committee (SEC) reportedly felt that there is no need of administering the third dose or the booster dose for the people and asked the company to come up with more data that proves the vaccine dose's capability of fighting the Omicron variant effectively.
In the wake of the possible threat posed by the Omicron variant, the Serum Institute had applied for the third dose of vaccine as the booster dose. In its application, the company said, it has the required stock of the doses to administer for the people. But the application was not accepted and the Committee sought more data.
Looking at the global scenario, various countries have already started the process of giving a third dose of the anti-Covid dose as a precautionary measure so that the virus won't get spread in the respective countries further.
So far, India's toll of Omicron cases has gone up to 26 after three new infections were detected the other day.
This gave birth to a demand that a third dose(booster) should be given to the people so that the vaccine can be stopped from infecting more people. States like Karnataka, Maharashtra have urged the Union government to permit the booster dose before the Omicron spreads its wings.
Amid this, the Pune-based Serum Institute of India(SII) which manufactured Covishield had reached out to the Central government's Subject Expert Committee (SEC) to seek approval for the booster dose. The Committee went through the application filed by the biotechnology company.
However, the booster dose did not get approval from the committee reportedly. The reason for this is that the committee is said to have asked Pune-based Biotechnology SII to submit more data on the vaccine dose in this regard.
Media reports say that the Subject Expert Committee (SEC) reportedly felt that there is no need of administering the third dose or the booster dose for the people and asked the company to come up with more data that proves the vaccine dose's capability of fighting the Omicron variant effectively.
In the wake of the possible threat posed by the Omicron variant, the Serum Institute had applied for the third dose of vaccine as the booster dose. In its application, the company said, it has the required stock of the doses to administer for the people. But the application was not accepted and the Committee sought more data.
Looking at the global scenario, various countries have already started the process of giving a third dose of the anti-Covid dose as a precautionary measure so that the virus won't get spread in the respective countries further.
So far, India's toll of Omicron cases has gone up to 26 after three new infections were detected the other day.